Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Background REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal
antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of …

Recent efforts to identify treatments for chronic diabetic complications have resulted in the
discovery of a novel series of highly potent and selective 3-[(benzothiazol-2-yl)methyl]indole-N…

Importance Easy-to-administer anti–SARS-CoV-2 treatments may be used to prevent
progression from asymptomatic infection to symptomatic disease and to reduce viral carriage. …

Background Open-label platform trials and a prospective meta-analysis suggest efficacy of
anti–interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 (…

Background There is an unmet need for COVID-19 prevention in patient populations who
have not mounted or are not expected to mount an adequate immune response to complete …

Background The open-label RECOVERY study reported improved survival in hospitalized,
SARS-CoV-2 seronegative patients treated with casirivimab and imdevimab (CAS + IMD). …

Dupilumab is a fully human monoclonal antibody directed against the interleukin (IL)‐4
receptor α subunit (IL‐4Rα) of IL‐4 heterodimeric type I and type II receptors that mediate IL‐4/IL‐…

This open‐label drug–drug interaction study assessed whether blockade by dupilumab of
interleukin (IL)‐4 and IL‐13 signaling affects the pharmacokinetics of drugs metabolized by …

Importance The monoclonal antibody combination of casirivimab and imdevimab reduced
viral load, hospitalization, or death when administered as a 1200-mg or greater intravenous (IV…